Literature DB >> 8078912

Parvovirus particles as platforms for protein presentation.

K Miyamura1, S Kajigaya, M Momoeda, S J Smith-Gill, N S Young.   

Abstract

Empty capsids of the human pathogenic parvovirus B19 can be produced in a baculovirus system. B19 capsids are composed mainly of major capsid protein (VP2) and a small amount of minor capsid protein (VP1); VP1 is identical to VP2 but contains an additional 227-aa N-terminal region ("unique" region). A portion of that region of VP1 is external to the capsid, and VP1 is not required for capsid formation. We substituted the unique region with a sequence encoding the 147 aa of hen egg white lysozyme (HEL) and constructed recombinant baculoviruses with variable amounts of retained VP1 sequence joined to the VP2 backbone. After cotransfection with VP2 baculovirus and expression in insect cells, capsids were purified by density sedimentation. Purified recombinant capsids contained HEL. External presentation of HEL was demonstrated by immunoprecipitation, ELISA, and immune electron microscopy using anti-lysozyme monoclonal antibodies or specific rabbit antisera. Empty particles showed enzymatic activity in a micrococcal cell wall digestion assay. Rabbits inoculated with capsids made antibodies to HEL. Intact heterologous protein can be incorporated in B19 particles and presented on the capsid surface, properties that may be useful in vaccine development, cell targeting, and gene therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8078912      PMCID: PMC44635          DOI: 10.1073/pnas.91.18.8507

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Presentation and immunogenicity of viral epitopes on the surface of hybrid hepatitis B virus core particles produced in bacteria.

Authors:  B E Clarke; A L Brown; K G Grace; G Z Hastings; F Brown; D J Rowlands; M J Francis
Journal:  J Gen Virol       Date:  1990-05       Impact factor: 3.891

2.  Antigen chimaeras of poliovirus as potential new vaccines.

Authors:  K L Burke; G Dunn; M Ferguson; P D Minor; J W Almond
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

3.  Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis.

Authors:  R O Shade; M C Blundell; S F Cotmore; P Tattersall; C R Astell
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Formation of empty B19 parvovirus capsids by the truncated minor capsid protein.

Authors:  S Wong; M Momoeda; A Field; S Kajigaya; N S Young
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

6.  Mapping the antigenic epitope for a monoclonal antibody against lysozyme.

Authors:  S J Smith-Gill; A C Wilson; M Potter; E M Prager; R J Feldmann; C R Mainhart
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

7.  Productive infection by B19 parvovirus of human erythroid bone marrow cells in vitro.

Authors:  K Ozawa; G Kurtzman; N Young
Journal:  Blood       Date:  1987-08       Impact factor: 22.113

8.  Site-directed mutagenesis of the catalytic residues Asp-52 and Glu-35 of chicken egg white lysozyme.

Authors:  B A Malcolm; S Rosenberg; M J Corey; J S Allen; A de Baetselier; J F Kirsch
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

9.  Immune response to B19 parvovirus and an antibody defect in persistent viral infection.

Authors:  G J Kurtzman; B J Cohen; A M Field; R Oseas; R M Blaese; N S Young
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

10.  Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures.

Authors:  K Ozawa; N Young
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

View more
  11 in total

1.  Parvovirus diagnostics and vaccine production in insect cells.

Authors:  J I Casal
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

2.  Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.

Authors:  H L Greenstone; J D Nieland; K E de Visser; M L De Bruijn; R Kirnbauer; R B Roden; D R Lowy; W M Kast; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

3.  Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity.

Authors:  Carlos Ros; Marco Gerber; Christoph Kempf
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

4.  Modest truncation of the major capsid protein abrogates B19 parvovirus capsid formation.

Authors:  M Kawase; M Momoeda; N S Young; S Kajigaya
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

5.  Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles.

Authors:  Sharmila Pejawar-Gaddy; Yogendra Rajawat; Zoe Hilioti; Jia Xue; Daniel F Gaddy; Olivera J Finn; Raphael P Viscidi; Ioannis Bossis
Journal:  Cancer Immunol Immunother       Date:  2010-07-21       Impact factor: 6.968

6.  Assembly and intracellular localization of the bluetongue virus core protein VP3.

Authors:  Alak Kanti Kar; Nao Iwatani; Polly Roy
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Truncated forms of viral VP2 proteins fused to EGFP assemble into fluorescent parvovirus-like particles.

Authors:  Leona Gilbert; Jouni Toivola; Outi Välilehto; Taija Saloniemi; Claire Cunningham; Daniel White; Anna R Mäkelä; Eila Korhonen; Matti Vuento; Christian Oker-Blom
Journal:  J Nanobiotechnology       Date:  2006-12-08       Impact factor: 10.435

Review 8.  Use of macromolecular assemblies as expression systems for peptides and synthetic vaccines.

Authors:  G P Lomonossoff; J E Johnson
Journal:  Curr Opin Struct Biol       Date:  1996-04       Impact factor: 6.809

9.  Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice.

Authors:  Chong Wang; Xuexing Zheng; Weiwei Gai; Gary Wong; Hualei Wang; Hongli Jin; Na Feng; Yongkun Zhao; Weijiao Zhang; Nan Li; Guoxing Zhao; Junfu Li; Jinghua Yan; Yuwei Gao; Guixue Hu; Songtao Yang; Xianzhu Xia
Journal:  Antiviral Res       Date:  2016-12-28       Impact factor: 5.970

10.  PCR-based detection and genetic characterization of porcine parvoviruses in South Korea in 2018.

Authors:  Hee-Chun Chung; Van-Giap Nguyen; Thi-My-Le Huynh; Yong-Ho Park; Kun-Taek Park; Bong-Kyun Park
Journal:  BMC Vet Res       Date:  2020-04-15       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.